Korea Q2 Roundup: Mixed Bag As Pandemic Buoys Some, Hits Others
Prescription Sales Recover But Marketing, One-Offs Have Impact
Executive Summary
Two SK Group affiliates benefit from COVID-19 vaccine manufacturing activities and US sales of novel drugs, while other factors such as a recovery in prescription sales, new launches and falling milestone payments affected results at other traditional South Korean pharma firms in the second quarter.